Oligodendroglioma Foundation

11/07/2026

The long-term results from the clinical trial saw patients survive well past the usual survival time for these types of tumors.

08/07/2026

Ein deutscher Impfstoff gegen aggressive Hirntumoren hat in einer Phase-1-Studie ermutigende Langzeitdaten geliefert. Nun sollen weitere Studien die Wirksamkeit des Ansatzes klären.

16/06/2026

AI and diagnostics

Researchers in Germany have developed a deep-learning AI system called “Hetairos” that can predict the molecular classification of brain and spinal cord tumors in minutes using standard histology slides. The system was trained on over 11,000 digitized tissue sections from 9,606 patients across 11 centers on four continents, with ground-truth diagnoses based on DNA methylation profiling, which is currently the gold standard for CNS tumor classification. It can distinguish 102 molecular tumor subtypes, covering nearly the full WHO classification spectrum for CNS tumors.

In a head-to-head comparison with five expert neuropathologists across 210 challenging cases, Hetairos achieved significantly higher diagnostic accuracy (68% vs ~30% for humans), and 84% when considering top-three predictions. In prospective testing, it produced molecular subtype predictions in about 12 minutes, compared to roughly 12 days for standard methylation-based diagnostics.

The AI also includes a confidence scoring system, with high-certainty predictions in 50-70% of cases reaching ~87-88% accuracy, and it can narrow broad differential diagnoses into a small number of likely subtypes. Importantly, it highlights the specific tissue regions driving its decisions, improving interpretability and clinical trust.

While this system shows great potential, additional validation in independent cohorts and further regulatory evaluation will be required before it can be approved for routine diagnostic clinical use.

Researchers launch Hetairos, an AI that predicts brain tumor molecular subtypes in 12 minutes from routine tissue slides, outperforming human experts.

23/02/2026

Geneeskunde: Met protonentherapie kunnen kankerpatiënten heel precies bestraald worden. Toen bleek dat patiënten met een specifieke hersentumor vroegtijdig overleden, werd voor deze groep de bestraling acuut stopgezet. Maar Wouter Slegt werd „gewoon keihard doorbehandeld”.

15/12/2025

https://www.businesstoday.in/industry/pharma/story/india-clears-new-brain-cancer-drug-expected-at-lower-price-than-us-and-europe-506048-2025-12-10

Servier India to launch Vorasidenib (Voranigo), a targeted therapy for patients with Grade 2 IDH-mutant glioma